
- Telehealth Visits
- Insurance plan information

Daniel Mathalon, MD, PhD
He | Him | HisPsychiatry- Telehealth Visits
- Insurance plan information



Daniel Mathalon, MD, PhD
He | Him | HisPsychiatry- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Daniel Mathalon is a psychiatrist who cares for patients who have recently developed or are at high risk of developing psychosis.
Using such methods as magnetic resonance imaging (MRI) and electroencephalography (EEG), Mathalon studies abnormalities in the brains of people with schizophrenia, looking at the range of patients from those who have the high-risk syndrome that sometimes develops into psychosis to those living with chronic psychosis. His current research specifically focuses on improving the ability to diagnose and treat the warning signs of psychosis before the condition fully develops, with a long-term goal of preventing psychosis and improving outcomes for young people with psychosis and their families.
Mathalon earned his doctorate in psychology at Indiana University and his medical degree at Stanford University School of Medicine, where he also completed a residency in psychiatry and a fellowship in psychophysiology.
Education & training
Board certification
- Psychiatry, American Board of Psychiatry and Neurology
Fellowship
- Psychiatry, Stanford University Medical Center-GME
Residency
- Psychiatry, Stanford University Medical Center-GME
Degree
- MD, Stanford University School of Medicine
My expertise
Specialties
Clinical Trials query: q=health_gateway_id_ss%3A%28%221888%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%221888%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.